PATRICK WONG, M.D.; ROBERT W. COLMAN, M.D., F.A.C.P.; RICHARD C. TALAMO, M.D.; BERNARD M. BABIOR, M.D., Ph.D.
The kallikrein-bradykinin system was studied in patients with chronic alcoholic liver disease. Kallikreinogen levels were depressed in patients with cirrhosis when compared with levels in normal control subjects (18.8 ± 4.3 SD µmoles/ml·hr and 97 ± 24 SD µmoles/ml·hr, respectively). Levels in cirrhotics with long prothrombin times (7.8 ± 2.8 SD µmoles/ml·hr) were lower than levels in cirrhotics with normal prothrombin times (35.2 ± 20 SD µmoles/ml·hr). The lowest levels (1.5 ± 1.2 SD µmoles/ml·hr) were in three patients with hepatorenal syndrome. In contrast, Hageman factor, kallikrein inhibitor, and bradykinin levels were normal or only moderately depressed. Free kallikrein was not detected. We conclude that kallikreinogen production is impaired in alcoholic liver disease, the degree of impairment correlating well with the severity of the liver disease, and that kallikreinogen levels therefore are a sensitive index of liver dysfunction. Strong evidence was presented that the hepatorenal syndrome is not caused by elevated plasma bradykinin levels.
WONG P, COLMAN RW, TALAMO RC, BABIOR BM. Kallikrein-Bradykinin System in Chronic Alcoholic Liver Disease. Ann Intern Med. ;77:205–209. doi: 10.7326/0003-4819-77-2-205
Download citation file:
Published: Ann Intern Med. 1972;77(2):205-209.
Gastroenterology/Hepatology, Liver Disease, Tobacco, Alcohol, and Other Substance Abuse.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use